Execution strong, margins beat 30% guide; growth engines ramping

Delivered ₹1,045 Cr, 44.1% YoY growth

Delivered exactly 34.2%, 566 bps expansion

Delivered ₹243.3 Cr, 107.7% YoY

Prior guidance 75–80 days; delivered 81 days

HPP ₹540 Cr (+33%), Spec Chem ₹325 Cr (+48%), CDMO ₹180 Cr (+82%)

Prior 30% ±1–2% (i.e., 28–32% range) vs. new 32–33% ±1% (i.e., 31–34% range); 200+ bps midpoint shift driven by HFC pricing and operational leverage.

Management disclosed advanced conversations to lock 35–45% of 24,000 MT total capacity over 5 years, addressing CY27–31 oversupply concerns.

₹90 Cr adoption capacity approved with phased execution; 4–5 products already lab-qualified, de-risking first commercial scale phase.

Phase 2 cGMP4 (₹125 Cr) initiated; European partner expanding molecule count (API minus 1); 30–40 pipeline disclosed, vs. prior vague sizing.

Data centers, electronics, semiconductors, defense; chip fabrication, cooling, display, OLEDs, fire suppressants, high-voltage electrical, wind energy (high-purity HF); advanced intermediates for fluoroelastomers, sealants, films, coatings.

Long-term demand doubles, supply halves (quota-driven). Near-term: lowest-cost manufacturer position, hybrid renewable power (60% green, reduces costs), operating leverage on 15,000 MT expansion, contracting strategy 35–45% over 5 years; global context (export-led for India CY27–31), not India-only demand-supply.

3x asset turn by FY'29 on ₹288 Cr capex (Phase 1 + 2); moving to API minus 1. Competitive positioning depends on asset turn, not direct answer to parity claim. Honestly don't know if competition has similar offer.

We are sole supplier; 15-month window still valid. Wait and see on scale-up timeline.

Navigating differently via 5 new molecules (3 patented, pricing power), deepened customer relationships, expanded footprint into innovators. MPP debottlenecking at 2x asset turn (unheard of in agchem); productivity gains offset pricing pressure.

30–40 molecule pipeline, 10 late-stage, 3–4 FY27 readouts; working with top 20 pharma, multiple molecules with different majors; therapeutic areas broad (oncology, respiratory, cardiovascular, neuro, animal health). Deepening provides baseload; breadth manages portfolio risk.

$100 million FY27 very much on track. 3x asset turn by FY'29 (possibly sooner), from ₹288 Cr capex base.

Increasing interest led to couple already contracted; more in recent stage of conclusion. Originally targeted 30%, now pursuing higher. Balanced approach: won't go beyond certain point to maintain open market position. AHF 60,000 MT (Surat + Dahej) good for next 4–5 years; interim downstream value-add (advanced materials) will absorb more.

Q1 FY26 HF prices very high. Today: heightened global tensions, supply chain risk, RM costs rising. Gross margin dip 100 bps Q4→Q1 offset by productivity. Lag effect on pricing pass-through. Normalized run-rate 32–33% ±1% over next 1–2 years with new capex.

4–5 products already lab-qualified; adoption capacity will scale to commercial qualification. Phased capex: first phase mid-Q4 FY'27, then qualify commercial sale quantities with customers, opening funnel for further capex. This is a 'wheel of fortune'—new products entering, commercialized ones exiting to MPP or dedicated capex.

Bound by confidentiality; product name and application beyond defense are out there. Application beyond defense is material opportunity for Navin. Cannot quantify impact.

HPP, Specialty, CDMO all tracking double-digit; capex projects (HFC Q3, Chemours Q2, CDMO Phase 2 Q4) add incremental momentum.

4–5 lab-qualified products provide de-risked base; execution risk on customer ramp-up and qualification timelines.

Q1 delivered 34.2% (cyclical HFC pricing uplift). Management expects normalization to 32–33% range as HF inflation cycles in and leverage from capex ramps.

CDMO running at implied high-margin profile; but quantified revenue contribution not yet specified; portfolio effect unquantified.

Board-approved, funded from internal accruals; stage-gated discipline with technical + commercial + financial clearances.

Value-accretive discipline; only pursued capex with strong RFQ/customer engagement visibility; asset-turn metrics not primary lever for high-margin business.

CY27–31 India oversupply expected; 15,000 MT new capacity added by Navin + incumbents + new players. Contracting strategy (35–45% locked) not yet executed; competitive offers unclear.

30–40 molecule pipeline with 10 late-stage; 3–4 FY27 FDA readout expected. One readout already failed ('not coming quite well'). Success rate risk on remaining pipeline; late-stage attrition unknown.

₹90 Cr adoption capex with 4–5 lab-qualified products; phased rollout to Q2 FY'28 and beyond. Scaling from lab to commercial scale carries risk; customer qualification timeline unquantified; funnel for further capex unproven.

Q1 EBITDA margin 34.2% benefited from elevated HFC pricing (relative to Q1 FY26 when HF prices were high). Management guidance normalizes to 32–33% ±1%, implying 100+ bps headwind. Raw material cost inflation (heightened global tensions, supply chain risk) acknowledged; lag effect on pricing pass-through.

Heightened global tensions, supply-chain risk, and uncertain macro backdrop cited by management. Potential impact on customer investment (data centers, semiconductors) and logistics. European CDMO partner exposure (tech-sensitive region).